EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

The Optimizing Lung Screening Trial (WF-20817CD)

Kristie L Foley, Emily V Dressler, Kathryn E Weaver, Erin L Sutfin, David P Miller, Christina Bellinger, Carol Kittel, Rebecca J Stone, W Jeffrey Petty, Stephanie R Land, John G Spangler, Glenn J Lesser und 2 weitere

CHEST · 2023-08 · 164 (2) · 531-543

DOI: 10.1016/j.chest.2023.03.013 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift CHEST, 2023-08. Verfasst von Kristie L Foley und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Implementation Science, Wake Forest University School of Medicine, Winston-Salem, NC. Electronic address: kfoley@wakehealth.edu. Hauptthemen laut MEDLINE: Tobacco Use Cessation, Smoking Cessation, Lung Neoplasms. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute, Wake Forest University School of Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: One-half of all people who undergo lung cancer screening (LCS) currently use tobacco. However, few published studies have explored how to implement effective tobacco use treatment optimally during the LCS encounter. RESEARCH QUESTION: Was the Optimizing Lung Screening intervention (OaSiS) effective at reducing tobacco use among patients undergoing LCS in community-based radiology facilities? STUDY DESIGN AND METHODS: The OaSiS study (National Cancer Institute [NCI] Protocol No.: WF-20817CD) is an effectiveness-implementation hybrid type II cluster randomized trial of radiology facilities conducted in partnership with the Wake Forest National Cancer Institute Community Oncology Research Program research base. We randomly assigned 26 radiology facilities in 20 states to the intervention or usual care group. Staff at intervention facilities implemented a variety of strategies targeting the clinic and care team. Eligible patient participants were aged 55 to 77 years undergoing LCS and currently using tobacco. Of 1,094 who completed a baseline survey (523 intervention group, 471 control group) immediately before the LCS appointment, 956 completed the 6-month follow-up (86% retention rate). Fifty-four percent of those who reported not using tobacco at 6 months completed biochemical verification via mailed cotinine assay. Generalized estimating equation marginal models were used in an intention-to-treat analysis to predict 7-day tobacco use abstinence. RESULTS: The average self-reported abstinence among participants varied considerably across facilities (0%-27%). Despite a significant increase in average cessation rate over time (0% at baseline to approximately 13% at 6 months; P < .0001), tobacco use did not differ by trial group at 14 days (OR, 0.96; 95% CI, 0.46-1.99; P = .90), 3 months (OR, 1.17; 95% CI, 0.69-1.99; P = .56), or 6 months (OR, 0.97; 95% CI, 0.65-1.43; P = .87). INTERPRETATION: The OaSiS trial participants showed a significant reduction in tobacco use over time, but no difference by trial arm was found. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT03291587; URL: www. CLINICALTRIALS: gov.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tobacco Use CessationSmoking CessationLung NeoplasmsHumansEarly Detection of CancerLung

Stichwörter der Autor:innen

NCORPcessationimplementationlung cancer screeningsmoking

Autor:innen und Institutionen

  • Department of Implementation Science, Wake Forest University School of Medicine, Winston-Salem, NC. Electronic address: kfoley@wakehealth.edu.
  • Department of Biostatistics and Data Science, Wake Forest University School of Medicine, Winston-Salem, NC.
  • Department of Implementation Science, Wake Forest University School of Medicine, Winston-Salem, NC; Department of Social Sciences and Health Policy, Wake Forest University School of Medicine, Winston-Salem, NC.
  • Department of Social Sciences and Health Policy, Wake Forest University School of Medicine, Winston-Salem, NC.
  • Department of Implementation Science, Wake Forest University School of Medicine, Winston-Salem, NC; Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC.
  • Department of Pulmonology and Critical Care, Wake Forest University School of Medicine, Winston-Salem, NC.

Förderung

  • NCI NIH HHS
  • National Cancer Institute
  • Wake Forest University School of Medicine

Zitieren

APA

Foley, K. L., Dressler, E. V., Weaver, K. E., Sutfin, E. L., Miller, D. P., Bellinger, C., Kittel, C., Stone, R. J., Petty, W. J., Land, S. R., Spangler, J. G., Lesser, G. J., Chiles, C., & Optimizing Lung Screening Trial Writing Team (2023). The Optimizing Lung Screening Trial (WF-20817CD). CHEST, 164(2), 531-543. https://doi.org/10.1016/j.chest.2023.03.013

Vancouver

Foley KL, Dressler EV, Weaver KE, Sutfin EL, Miller DP, Bellinger C, et al. The Optimizing Lung Screening Trial (WF-20817CD). CHEST. 2023;164(2):531-543. doi:10.1016/j.chest.2023.03.013

BibTeX
@article{Foley2023,
  author = {Foley, Kristie L and Dressler, Emily V and Weaver, Kathryn E and Sutfin, Erin L and Miller, David P and Bellinger, Christina and Kittel, Carol and Stone, Rebecca J and Petty, W Jeffrey and Land, Stephanie R and Spangler, John G and Lesser, Glenn J and Chiles, Caroline and Optimizing Lung Screening Trial Writing Team, Optimizing Lung Screening Trial Writing Team},
  title = {The Optimizing Lung Screening Trial (WF-20817CD)},
  journal = {CHEST},
  year = {2023},
  volume = {164},
  number = {2},
  pages = {531--543},
  doi = {10.1016/j.chest.2023.03.013}
}
Kostenlos starten →